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Background 
Objectives 
Staphylococcus aureus is a gram positive ubiquitous pathogen that [1,2] may cause a variety of diseases ranging from moderate to severe skin and soft tissue infections to serious infections. [3,4]. 
Over the past decade different clonal types resistant to a wide range of antibiotics have emerged, as well as methicillin resistant Staphylococcus aureus (MRSA) [4,5], and becoming the 
predominant strain in S. aureus infections [2]. This increased underlines the need to develop new strategies to prevent infection by S. aureus [2]. 
Despite the need for a S. aureus vaccine and the continuing efforts of the scientific community, clinical trials have failed [1]. This emphasizes the need to develop new vaccine strategies that 
provide cellular memory, particularly Th17 [2,5]. 
§To develop a vaccine strategy against Staphylococcus aureus that involves multiple antigens that would trigger various immune mechanisms, especially Th17-mediated response and IL17, is 
essential for eliminating the infection. 
§Mass vaccination strategy for the general public, including sectors of the population with a high risk of infection. 
S. aureus immunology
Even though S. aureus stimulates the
humoral response, this may not play an 
important role in the removal of the 
pathogen [6]. 
The main immune mechanisms required 
for protection against staphylococcal 
infections include neutrophils and T cells, 
which regulate the phagocytic activity [3]. 
Various studies establish the connection 
between T cells and neutrophils through 
the IL-17 cytokine, which is important for 
the recruitment and activation of 
neutrophils at the site of infection, 
increases chemotaxis and their 
synergistic actions with the TLR2 (Figure 
1) [2,6]. 
 
Isd system 
Iron is essential in the pathogenesiS [2,7]. S. aureus has 
developed a collection system called iron-regulated surface 
determinants (Isd) for heme acquisition [7]. Isd system is 
comprised of cell wall-anchored surface proteins (IsdA, IsdB, IsdC 
and IsdH), a membrane transporter (IsdD, IsdE and IsdF), a 
transpeptidase (SrtB) and two cytoplasmatic heme-degrading 
monooxygenases (IsdG and IsdH) (Figure 2) [7,8].  
The Joshi et al. study using a murine sepsis model demonstrated 
that the protein IsdB provides cellular immunity, specifically Th17. 
They also found pre-existing titers of antibodies against this protein 
in serum of various mammals [6]. 
This project will make a subunit vaccine consisting of Isd system 
surface proteins, IsdA, IsdB, IsdC and IsdH, formulated with 
AAHSA (amorphous aluminum hydroxyphosphate sulfate 
adjuvant).  
Expected results 
The vaccine formed by the Isd system surface proteins 
should provide protective memory against S. aureus. The 
immune response must be mediated by Th17 cells, so 
that it is expected to increase production of the cytokine 
IL-17 and th17 cell in the vaccinated individuals compared 
to the control ones. Likewise an increase of survival in 
mice immunized in the lethal challenge is expected. It 
should also increase the titer of antibodies against 
proteins of the vaccine as a consequence of enhancing 
the T response [6,9,10]. 
Material and Methods
The project provides a solution to a major problem of 
public health, which is the increasing infections by 
S.aureus, particularly multi-resistant strains. 
The scientific community has attempted to solve this 
problem from different angles, but so far has failed.  
This project offers an easily constructed vaccine that 
steers the immune response to a cellular one, more 
particularly to Th17 which is essential to bacterial 
clearance. Moreover, the vaccine is composed of various 
antigens, resulting in a multivalent approach. 
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Figure 1: IL-17 activates production of antimicrobial peptides, 
chemokines and adhesion molecules that promote the recruitment of 
neutrophils from the circulation to the site of infection. Neutrophils 
help control infection spread and are required for bacterial 
clearance. IL-17-mediated signalling also promotes TH17 cells 
recruitment [14]. 
Figure 2: The different Isd system components 
involved in heme uptake (red star) of/from 
hemoglobin (Hb) [13]. 
PCR amplify genes isdA, isdB, isdC and isdH 
adding restriction enzyme targets BamHI and 
NdeI (Figure 3) (Table 2) 
Separete PCR product by agarose eletrophoresis 
Murine sepsis model and lethal challenge 
Cut the plasmid pET-15b and PCR products with 
BamHI and NdeI 
Ligation (Figure 3) 
Transform in E. coli BL21 (DE3) by 
electroporation  
Selection the plasmids with the insert in LB + 
Amp 
Seed the colonies in LB liquid medium until an 
Abs600nm = 0.8 
Induce expresion of T7 RNA polymerase with 
IPTG for 3 hours 
Lyse cells by sonication 
Recovering chimeric proteins (Figure 3) 
Purify proteins that are labelled with a histidine 
tag in an affinity chromatography 
Remove histidine tail with thrombin 
Purify proteins by gel filtration 
Formulate puryfy protein with adjuvant AAHSA 
Vaccine: 20mg/dose antigen + 
450mg/dose AAHSA 
Control: 450mg/dose AAHSA 
Inject 50 µl/doses intramuscularly to BALB/c mice 
on days 0, 7 and 21 (Figure 4) 
Day 28: perform and ELISA to determine 
antibody titer and a flow citometry to determine 
Th17 levels (Figure 4) 
Day 35: infect mice with lethal dose of S. aureus. 
Perform a  survival study of 10 days (Figure 4) 
Perform a statistical  analysis 
Antigens production 
After the concession of the project, undertake the 
necessary research and experiments to obtain viable 
results and to perform a patent. Submit an application to 
the Oficina Española de Patentes y Marcas (OEPM 
http://www.oepm.es/es/index.html) with international 
scope by applying the Patents Cooperation Treaty (PCT). 
Once the patent is granted, publish one or more scientific 
papers with the obtained results so far in one of the 
following scientific journals:  
•Vaccine (http://www.journals.elsevier.com/vaccine/)  
•Journal of Bacteriology (http://jb.asm.org/). 
Project dissemination 
Table 2: Primers 
IsdAF 5’- CATCATG GCAGAAAATACAAATA -3’ 
IsdAR 5’- GGATCCTTTACATTTTAGATTGACT-3’ 
IsdBF 5’- CATCATGTTATTTAGATTCTTTTCT -3’ 
IsdBR 5’- GGATCCATGACAAAACATTAT -3’ 
IsdCF 5’- CATCATGTTAGTTTTTACGTTTTCT -3’ 
IsdCR 5’- GGATCCATGAACAAACAGC -3’ 
IsdHF 5’- CATCATGTTGAAAAATATTTTAAAAG -3’ 
IsdHR 5’- GGATCCTTATTCCACATTGC -3’ 
pET-15bF 5’- GATCTCGATCCCGCGAA-3’ 
pET-15bR 5’- CCTCAAATGGGCTCTTAAAACC-3’ 
Figure 3: Sketch of genic construction 
used in gene amplification for the 
production of antigens and chimeric 
protein obtained. 
Figure 4: Murine sepsis model and 
lethal challenge diagram to test  the S. 
aureus vaccine developed in this 
project.  
